. 2019 Feb 26;10(1):35–45. doi: 10.14740/wjon1179

Table 1. Baseline Characteristics of Adenocarcinoma Without Active EGFR Mutations.

	All	LIPI			P
	All	Good	Intermediate	Poor	P
N	175	85	68	22
Backgrounds
Sex (N), male/female	120/55	55/30	47/21	18/4	0.33^a
Age (years), median (IQR)	68 (62.4 - 74.6)	68 (63.5 - 74.9)	65 (60.2 - 74.5)	69 (64.0 - 71.5)	0.49^b
Smoking status, none/former/current smokers	30/56/89	14/26/45	13/24/31	3/6/13	0.85^a
PD-L1 status, ≥ 50%/1-49%/< 1%/NA	8/5/1/161	6/4/1/74	2/0/0/66	0/0/0/22	0.25^a
ECOG-PS, 0 - 1/≥ 2	136/39	76/9	52/16	8/14	< 0.01^a
Stage, IIIB/IV/recurrence	32/132/11	20/57/8	12/56/0	0/19/3	< 0.01^a
Metastatic sites, ≥ 2	89	38	33	18	0.06^a
First-line chemotherapy
Regimen
Single/combination (N)	7/168	4/81	3/65	0/22	0.88^a
Pemetrexed-containing (N)	84	40	33	11	0.96^a
Bevacizumab-containing	35	24	9	2	0.03^a
Efficacy
ORR (%) (95% CI)	39.4 (32.1 - 47.1)	55.3 (44.1 - 66.1)	30.9 (20.2 - 43.3)	18.2 (5.2 - 40.3)	< 0.01^a
DCR (%) (95% CI)	70.9 (63.5 - 77.5)	82.4 (72.6 - 89.8)	64.7 (52.2 - 75.9)	45.5 (24.4 - 67.8)	< 0.01^a
Second and further line
Second-line (N)	107	57	41	9	0.08^a
Immuno-checkpoint inhibitor (N)	25	18	7	0	0.02^a
Laboratory data
dNLR
Median (IQR)	2.08 (1.61 - 2.98)	1.82 (1.30 - 2.06)	2.69 (1.89 - 3.12)	3.96 (3.64 - 5.58)	< 0.01^b
≥ 3 (N)	132	85	47	0	< 0.01^a
LDH
Median (IQR)	203 (170 - 265)	174 (154 - 200)	247 (207 - 311)	298 (244 - 415)	< 0.01^b
> ULN (N)	69	0	47	22	< 0.01^a

CI: confidence interval; DCR: disease control rate; dNLR: derived neutrophil-to-lymphocyte ratio; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; IQR: interquartile range; LDH: lactate dehydrogenase; LIPI: lung immune prognostic index; NA: not assessed; ORR: overall response rate; ULN: upper limit of normal. ^aFisher’s exact test; ^bKruskal-Wallis rank sum test.